(HealthDay)—In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.
Oct 15, 2019
0
0
(HealthDay)—Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism (VTE) in morbidly obese patients, with similar safety and efficacy as warfarin, according to a study published ...
Sep 30, 2019
0
2
(HealthDay)—Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept. 20 issue ...
Sep 20, 2018
0
0
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and ...
Aug 27, 2018
0
0
Bleeding in patients treated with anticoagulants should stimulate a search for cancer, according to late breaking results from the COMPASS trial presented today at ESC Congress 2018.
Aug 26, 2018
0
0
NUS pharmaceutical scientists have developed a prediction model to guide dosage adjustments of rivaroxaban, an oral anticoagulant (blood thinner), in renal-impaired patients taking amiodarone. This is to reduce the risk of ...
May 22, 2018
0
2
Research from the University of Warwick indicates that taking a tablet a day can help treat cancer patients of a potentially deadly condition.
May 11, 2018
0
13
A multicentre, double-blind, randomized, controlled clinical trial of patients who underwent total hip or knee replacement surgery showed that aspirin was as effective as rivaroxaban, the standard anti-coagulation medication, ...
Mar 13, 2018
0
283
(HealthDay)—For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. ...
Sep 12, 2017
0
2
(HealthDay)—The safety and efficacy of rivaroxaban treatment for nonvalvular atrial fibrillation (AF) in patients with active cancer is similar to the general population, according to a study published in the July 15 issue ...
Jul 13, 2017
0
0
